We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
Read MoreHide Full Article
Key Takeaways
Pfizer raised revenue guidance as non-COVID strength offset a $1 billion cut to expected COVID sales.
Launched and acquired products generated $3.2 billion and grew 18% operationally during the quarter.
Pfizer targets $2.5 billion in added savings through 2029 while funding oncology and obesity R&D.
Pfizer Inc. (PFE - Free Report) used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity.
Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call also clarified expectations for pipeline readouts central to Pfizer’s post-2028 growth plan.
PFE Raises Revenue Outlook Despite COVID Drag
Incoming Interim CFO Cecile Guegan said full-year revenue guidance now stands at $60.5 billion to $62.5 billion, up $500 million at the midpoint. Better-than-expected non-COVID performance added about $1.5 billion to the outlook.
That strength was offset by a $1 billion reduction in expected COVID-19 revenue to about $4 billion. Guegan said low infection levels are limiting Paxlovid, while Comirnaty sales remain weighted toward the vaccination season.
Adjusted EPS of $0.77 topped the Zacks Consensus Estimate of $0.68. Revenue of $15.03 billion beat the $14.45 billion estimate.
Guegan said launched and acquired products generated $3.2 billion and grew 18% operationally. Excluding prior-year one-time effects, growth was 27%.
CEO Albert Bourla highlighted Seagen, Metsera and Biohaven as Pfizer’s transaction platforms. He said the legacy Seagen portfolio delivered 21% U.S. growth after excluding a prior-year stocking benefit, while Nurtec posted strong growth.
Chief U.S. commercial officer Aamir Malik told a JPMorgan analyst that Padcev’s growth rate should moderate as advanced-disease penetration rises. Further upside should come from muscle-invasive bladder cancer and the bladder-sparing study.
PFE Expands Savings While Funding R&D
Guegan outlined $2.5 billion of additional net savings expected from 2027 through 2029. The plan includes $1 billion from technology and simplification and $1.5 billion from manufacturing optimization.
Pfizer now expects $6.7 billion of net savings from cost realignment and $3 billion from manufacturing optimization through 2029. Guegan said the measures should support margin expansion and investment.
Adjusted gross margin was 76% and adjusted operating margin was 35%. Adjusted R&D expense rose 12% operationally as spending increased on oncology and obesity candidates, while adjusted SI&A expense fell 3% operationally.
Pfizer Sets a High Bar for Pipeline Catalysts
Chief scientific officer Chris Boshoff said Pfizer expects five regulatory decisions, eight key readouts and 19 pivotal study starts over the next 12 months. Management targets a risk-adjusted high-single-digit revenue CAGR from year-end 2028 through 2033.
A BMO Capital Markets analyst asked about the fourth-quarter MEVPRO-1 prostate cancer readout. Boshoff said the event-driven study is designed around an approximately 30% clinically meaningful benefit over standard care and confirmed that the required events had not been reached.
Berobenatide has 10 Phase III studies planned in 2026 and a first approval targeted for 2028. Boshoff told a Citi analyst that Pfizer wants the monthly amylin combination to outperform berobenatide alone, with SOLIS-1 data expected in 2027.
PFE Defends Dividend and Limits Deal Size
A Morgan Stanley analyst asked what could prompt a dividend cut. Bourla said Pfizer expects to maintain the dividend even under its most stretched scenarios and resume growth after the loss-of-exclusivity period.
Guegan put business development capacity at about $6 billion after the Innovent transaction. She said leverage ended the quarter at 2.7 times and could remain near that level or move modestly higher during the transition.
Bourla said future transactions should be smaller bolt-ons. He identified oncology, immuno-inflammation, obesity and vaccines as the areas where Pfizer will remain selective.
Pfizer’s Priorities After the Call
Management’s posture centered on execution through the patent-loss period: protect the dividend, use savings to fund the pipeline and rely on launched and acquired products to offset COVID weakness and exclusivity losses.
The near-term focus is commercial follow-through in Padcev and Nurtec, obesity-program execution and a dense slate of oncology and immunology catalysts over the coming year.
The mix does not match the stronger combination of a Zacks Rank #1 or #2 with an A or B Style Score. The Zacks Rank can change as earnings estimates are revised after the just-reported results.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
Key Takeaways
Pfizer Inc. (PFE - Free Report) used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity.
Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call also clarified expectations for pipeline readouts central to Pfizer’s post-2028 growth plan.
PFE Raises Revenue Outlook Despite COVID Drag
Incoming Interim CFO Cecile Guegan said full-year revenue guidance now stands at $60.5 billion to $62.5 billion, up $500 million at the midpoint. Better-than-expected non-COVID performance added about $1.5 billion to the outlook.
That strength was offset by a $1 billion reduction in expected COVID-19 revenue to about $4 billion. Guegan said low infection levels are limiting Paxlovid, while Comirnaty sales remain weighted toward the vaccination season.
Adjusted EPS of $0.77 topped the Zacks Consensus Estimate of $0.68. Revenue of $15.03 billion beat the $14.45 billion estimate.
Pfizer Inc. Price, Consensus and EPS Surprise
Pfizer Inc. price-consensus-eps-surprise-chart | Pfizer Inc. Quote
Pfizer Leans on Launches and Acquired Assets
Guegan said launched and acquired products generated $3.2 billion and grew 18% operationally. Excluding prior-year one-time effects, growth was 27%.
CEO Albert Bourla highlighted Seagen, Metsera and Biohaven as Pfizer’s transaction platforms. He said the legacy Seagen portfolio delivered 21% U.S. growth after excluding a prior-year stocking benefit, while Nurtec posted strong growth.
Chief U.S. commercial officer Aamir Malik told a JPMorgan analyst that Padcev’s growth rate should moderate as advanced-disease penetration rises. Further upside should come from muscle-invasive bladder cancer and the bladder-sparing study.
PFE Expands Savings While Funding R&D
Guegan outlined $2.5 billion of additional net savings expected from 2027 through 2029. The plan includes $1 billion from technology and simplification and $1.5 billion from manufacturing optimization.
Pfizer now expects $6.7 billion of net savings from cost realignment and $3 billion from manufacturing optimization through 2029. Guegan said the measures should support margin expansion and investment.
Adjusted gross margin was 76% and adjusted operating margin was 35%. Adjusted R&D expense rose 12% operationally as spending increased on oncology and obesity candidates, while adjusted SI&A expense fell 3% operationally.
Pfizer Sets a High Bar for Pipeline Catalysts
Chief scientific officer Chris Boshoff said Pfizer expects five regulatory decisions, eight key readouts and 19 pivotal study starts over the next 12 months. Management targets a risk-adjusted high-single-digit revenue CAGR from year-end 2028 through 2033.
A BMO Capital Markets analyst asked about the fourth-quarter MEVPRO-1 prostate cancer readout. Boshoff said the event-driven study is designed around an approximately 30% clinically meaningful benefit over standard care and confirmed that the required events had not been reached.
Berobenatide has 10 Phase III studies planned in 2026 and a first approval targeted for 2028. Boshoff told a Citi analyst that Pfizer wants the monthly amylin combination to outperform berobenatide alone, with SOLIS-1 data expected in 2027.
PFE Defends Dividend and Limits Deal Size
A Morgan Stanley analyst asked what could prompt a dividend cut. Bourla said Pfizer expects to maintain the dividend even under its most stretched scenarios and resume growth after the loss-of-exclusivity period.
Guegan put business development capacity at about $6 billion after the Innovent transaction. She said leverage ended the quarter at 2.7 times and could remain near that level or move modestly higher during the transition.
Bourla said future transactions should be smaller bolt-ons. He identified oncology, immuno-inflammation, obesity and vaccines as the areas where Pfizer will remain selective.
Pfizer’s Priorities After the Call
Management’s posture centered on execution through the patent-loss period: protect the dividend, use savings to fund the pipeline and rely on launched and acquired products to offset COVID weakness and exclusivity losses.
The near-term focus is commercial follow-through in Padcev and Nurtec, obesity-program execution and a dense slate of oncology and immunology catalysts over the coming year.
Zacks Signals for PFE
PFE carries a Zacks Rank #3 (Hold). Its Value Score of A is favorable, while the Growth Score of D and Momentum Score of F indicate weaker readings. The VGM Score of C reflects a middle-range combined profile.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The mix does not match the stronger combination of a Zacks Rank #1 or #2 with an A or B Style Score. The Zacks Rank can change as earnings estimates are revised after the just-reported results.